Summer Sale: Buy 2, Get 1 Free on Hematopoietic Cells Products
From July 1st to August 31st, 2024, take advantage of exceptional savings on our hematopoietic cell products: PBMC, MNC-CB, and CD34+ Hematopoietic Progenitors. Contact us at commercial@abcell-bio.com for more information.
Abcell-bio Secures CIR Agreement from French Ministry: Offering Enhanced Access to Cord Blood Cells and Tax Benefits for R&D Partners
Abcell-bio arose from the will to accompany research by facilitating the access to primary resources which are difficult to get, especially cells from cord blood.
With a strong and unique network of French maternities and a robust production process, Abcell-bio also develops a Research & Development activity to face the challenges of the upcoming research.
Did you say Red September?
Every year, we hear about Pink October and Movember, but Red September isn’t as widely recognized. This month is dedicated to raising awareness for blood cancers, which affect 45,000 individuals annually in France. ‘Live with a MPN’, a patient association, launched this initiative last year and is now rolling out its second edition.
Abcell-bio offers an M2 internship position
Abcell-bio offers an M2 internship position for its R&D project on isolated CD34+ cells from cord blood.
Humanized mice using CD34+ from cord blood for investigating malaria parasite
This article describe a new humanized mice model that is a unique tool for investigating, in vivo, the biology of Plasmodium vivax, the most widespread human malaria parasite. This new model of humanized mice using CD34+ cells from cord blood (purchased from Abcell-bio company), allows a reconstitution of the human erythropoiesis.
Ex vivo expansion of hematopoietic progenitors: interest of a new bioactive peptide.
Although umbilical cord blood (UCB) is a promising source of Hematopoietic stem and progenitor cells (HSPCs), the low dose of HSPCs in these preparations limits their use, prompting need for ex vivo HSPC expansion. This study reports the development of a bioactive peptide named SL-13R, the design of which was originally derived from sequence of the extracellular […]
Risks associated with COVID-19 in pregnancy.
This article describe a new humanized mice model that is a unique tool for investigating, in vivo, the biology of Plasmodium vivax, the most widespread human malaria parasite. This new model of humanized mice using CD34+ cells from cord blood (purchased from Abcell-bio company), allows a reconstitution of the human erythropoiesis. Conclusion: This model holds promise for understanding in vivo host-parasite […]
Human Umbilical Vein Endothelial Cell Support Bone Formation of Adipose-Derived Stem Cell
This study aims at investigating the co-implantation of human adipose-derived stem cells (ADSCs) after osteogenic differentiation and human umbilical vein endothelial cells (HUVECs) embedded in a vascularized osteogenic matrix of hydroxyapatite (HAp) ceramic for bone tissue engineering. Interestingly, the implantation of HUVEC led to bone formation, suggesting that implanted HUVEC stimulated bone formation. This result […]
Abcell-bio is now part of the France Biotech network!
Biotechnology laboratory, Abcell-bio produces quality primary human cells from perinatal tissues. Our team is made up of dedicated scientists, whose objective is to facilitate the R&D work of our customers by forging real partnerships. As such, Abcell-bio is now part of the France Biotech network, whose role is to federate HealthTechs and MedTechs companies in […]
Which are the factors affecting human umbilical cord blood quality before cryopreservation?
Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSCs). Comparatively, UCB HSCs have an extensive proliferative capacity that exceeds that of bone marrow HSCs. However, the small quantity of HSCs obtained from an umbilical cord remains a problematic element restricting the usage of UCB and the quality of UCB units has […]